CareLit · DOI-Nachweis · Zeitschrift für Gastroenterologie
Low frequency of drug-drug interactions (DDIs) with the novel all oral antivirals elbasvir (EBV) and grazoprevir (GRZ) in patients with HCV genotype 1 infection in German real-world
DOI 10.1055/s-0036-1587006
Bibliografische Angaben
Nachweis in CareLit
Autor:innenP Buggisch, H Löhr, G Teuber, H Steffens, M Kraus, P Geyer, B Weber, T Witthöft, U Naumann, E Zehnter, D Hartmann, B Dreher, M Bilzer
ZeitschriftZeitschrift für Gastroenterologie
Ausgabe08/2016
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Background: The effectiveness of HCV treatment has dramatically improved with the approval of direct-acting antivirals (DAAs). However, a high frequency of clinically relevant DDIs between the regular outpatient medications and DAAs has been reported for HCV treatment with sofosbuvir in combination with simeprevir, daclatasvir or ledipasvir (30%-40%) while patients (pts) treated with ombitasvir/paritaprevir/ritonavi…
Zitieren
Zitierempfehlung
P Buggisch, H Löhr, G Teuber, H Steffens, M Kraus, P Geyer, B Weber, T Witthöft, U Naumann, E Zehnter, D Hartmann, B Dreher, M Bilzer (2016) Low frequency of drug-drug interactions (DDIs) with the novel all oral antivirals elbasvir (EBV) and grazoprevir (GRZ) in patients with HCV genotype 1 infection in German real-world. Zeitschrift für Gastroenterologie (08). https://doi.org/10.1055/s-0036-1587006
Mit CareLit weiterarbeiten